Claim OwnershipGeneInCell
Subscribed: 0Played: 7
Subscribe
© Vinod Reddy Lekkala
Description
GeneInCell-The AI-powered Biotech Podcast focuses on crisp, science-based podcasts on stem cells, organoids, and gene editing—tracking breakthroughs from bench to bedside for better human health, including Biotech and business.
30 Episodes
Reverse
NAMs are changing how new drugs are developed. We discuss organoids, tissue chips, and AI-based tools, along with the growing FDA and NIH push toward more human-relevant methods that can improve prediction, reduce reliance on animal models, and help bring safer treatments forward faster.
Can we grow new kidneys from stem cells? In this episode, we explore how scientists are using pluripotent stem cells to create kidney organoids that mimic early kidney development. We discuss how these mini-organs help study kidney disease, test new drugs, and move us closer to future regenerative therapies for kidney failure.
What really happens to your cells under stress, in space, and during space travel? In this episode, we zoom in on the physiological, cellular, and molecular levels to uncover how zero gravity affects them.
What does it take to grow a beating human heart in the lab? This episode explores cardiac organoids—self-organizing heart tissues derived from human stem cells that contract, respond to drugs, and model human heart disease. We unpack how iPSCs are guided into cardiac lineages, how electrical and mechanical cues drive maturation, and why these beating mini-hearts are transforming drug safety testing, disease modeling, and the future of regenerative cardiology.
In this episode, we explore the AI revolution in healthcare and what 2026 could look like—from smarter diagnostics and personalized treatments to automation that reshapes clinical workflows. We break down the key innovations, emerging trends, and real-world impact of AI on patients, clinicians, and the healthcare system.
Synthetic biology is turning cells into programmable factories, sensors, and therapies. In this episode, we explore how DNA can be engineered like code to build smarter medicines, sustainable biomaterials, and living devices—and what it will take to move these innovations from the lab to the real world.
How do you give “mini-brains” a bloodstream? This episode explores vascular brain organoids—cerebral organoids engineered with endothelial cells, pericytes, and astrocytes to form BBB-like barriers, improve oxygen/nutrient delivery, and accelerate neuronal maturation. We cover why perfusion matters for MEA activity and drug testing, how microvessels enable neurovascular-coupling studies, and what it will take to scale these tissues for translational neuroscience.
Brain organoids are self-organizing “mini-brains” grown from human stem cells that recapitulate key aspects of early neural development. They fire neural networks on MEAs, model neurodevelopmental and neurodegenerative diseases, and offer human-relevant platforms for drug discovery, circuit mapping, and studying brain evolution—while raising important questions about maturity, reproducibility, and ethics.
Grow a “mini-gut” from stem cells—fast. This episode maps the journey from pluripotent cells to functional intestinal organoids, covering key signals (Activin A, Wnt3a/R-spondin, EGF), culture formats (3D domes vs. monolayers), and core readouts (TEER, permeability, metabolism). We highlight use cases in disease modeling and drug testing.
Discover how 3D intestinal organoids—mini-gut tissues grown from stem cells—are transforming preclinical drug testing. We break down how these models capture human barrier function, absorption, metabolism, and host–microbiome interactions better than animal systems, enabling smarter toxicity profiling and efficacy screening. From patient-derived organoids for precision medicine to organoid-on-chip platforms, we cover practical workflows, readouts (TEER, imaging, omics), and what it takes to translate in-vitro hits into clinical candidates.
Silicon is hitting its limits—and our data keeps exploding. In this episode, we explore DNA as a radical new archive: a medium with hyper-dense capacity and millennia-scale stability that doesn’t need power to preserve information. We unpack the workflow—encoding 1s and 0s into A, T, C, and G; writing short DNA oligos; and reading them back with sequencing plus robust error-correction.
Explore the shift from standard Cas9 nuclease—which makes double-strand breaks—to precision tools like Cas9 nickases (single-strand “nicks”) and dead Cas9 (binding without cutting). We break down how these variants reduce off-target indels and enable safer editing and gene regulation (CRISPRi/a, base/prime editor scaffolds) for high-fidelity genome engineering.
From stem cells to therapies, this episode dives into the world of human liver organoids—how iPSCs are guided into functional “mini-livers,” the bioengineering tricks that mature them, and the breakthroughs they enable in disease modeling, drug screening, and precision hepatology. In this short episode, we unpack what’s real, what’s next, and how organoids are accelerating the path to regenerative treatments.
How PiggyBac moves DNA in—and out—without scars. We cover transposase mechanics (TTAA-site integration and footprint-free excision), large cargo delivery (tens to ~100 kb), and why it’s popular for iPSCs, stable cell lines, and cell therapies.
A quick tour of next-gen models that add functional vascularization and immune cells to boost physiological relevance. And strategies (self-assembly, pre-patterning) to build perfusable microvascular networks for real maturation.Educational only; not medical advice.
How FOXP3-defined Tregs prevent autoimmunity and shape therapy. We trace the discoveries by Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi, unpack Treg biology and assays, and explore translational angles—from autoimmune disease and transplantation to cancer immunotherapy and engineered Tregs. Educational content only; not medical advice.
How do you turn genes on with CRISPR—without making a single cut? This episode breaks down dCas9-based activators (VP64, p300, SAM, VPR, SunTag), guide design near promoters/enhancers. We compare strengths, limits, and off-target risks. Clear takeaways on assays (qPCR, RNA-seq, ATAC-seq, reporter readouts), durability, and safety considerations for translational work. Educational only; not medical advice.
In this episode, we explore how turning off defective genes is becoming a crucial aspect of modern medicine. Educational only; not medical advice.
Dive into the fascinating world of antisense oligonucleotides (ASOs) with this insightful podcast series. Explore the journey from genetic sequencing to groundbreaking therapeutic applications, uncovering how these innovative molecules are transforming the treatment of genetic disorders and beyond. Hosted by experts from GeneInCell, this series blends cutting-edge science with real-world impact, offering a deep dive into the future of precision medicine. Tune in to stay ahead in the evolution of human health!Educational content only; not medical advice.
How modern AI is rewiring the life-science stack—from target discovery to first-in-human. This episode unpacks foundation models for proteins/RNAs, generative chemistry, AI-guided ADMET/PK, phenotypic screening on organoids with high-content imaging, multi-omics integration, and self-driving labs with active learning. We compare what’s hype vs. real, walk through validation loops (prospective wet-lab tests, reproducibility, bias control), and map the path to clinic and regulation. Case studies highlight wins and failures—and where AI can truly compress timelines and costs.Educational content only; not medical advice
Comments
Download from Google Play
Download from App Store
United States